



AT7519 (trifluoroacetate)

Catalog No: tcsc1167

Available Sizes
Size: 5mg
Size: 10mg
Size: 50mg
Size: 100mg
Specifications
CAS No: 1431697-85-6
Formula: C ₁₈ H ₁₈ Cl ₂ F ₃ N ₅ O ₄
Pathway: Cell Cycle/DNA Damage
Target: CDK
Purity / Grade: >98%
Solubility: 10 mM in DMSO
Observed Molecular Weight: 496.27

Product Description

AT7519 trifluoroacetate as a potent inhibitor of **CDKs**, with $\mathbf{IC_{50}}$ s of 210, 47, 100, 13, 170, and





IC50 & Target: IC50: [2]

In Vitro: AT7519 (0-4 μM) results in dose-dependent cytotoxicity with IC $_{50}$ s ranging from 0.5 to 2 μM in MM cells, and this induced cytotoxicity is associated with GSK-3 β activation independent of transcriptional inhibition. AT7519 overcomes proliferative advantage conferred by cytokines and the protective effect of BMSC. AT7519 (0.5 μM) induces apoptosis of MM cells in a time-dependent manner. Moreover, AT7519 (0.5 μM) inhibits phosphorylation of RNA polymerase II CTD and partially inhibits RNA synthesis in MM.1S cells^[1]. AT7519 (250 nM) inhibits cell cycle progression in human tumor cell lines. AT7519 also induces apoptosis of human tumor cell lines. Furthermore, AT7519 inhibits RNA polymerase II and reduces antiapoptotic protein levels^[3].

In Vivo: AT7519 inhibits tumor growth in a human MM xenograft mouse model^[1]. AT7519 (4.6 and 9.1 mg/kg/dose) inhibits the growth of early-stage HCT116 tumor xenografts. AT7519 (10 mg/kg, i.p.) also inhibits the target CDKs in HCT116 tumor-bearing BALB/c nude mice^[2].

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!